Palivizumab : A Viewpoint by Eric A. F. Simoes

Simoes, E.A.F.
August 1999
Drugs;Aug1999, Vol. 58 Issue 2, p312
Academic Journal
Comments on the use of humanized monoclonal antibodies called palivizumab in the treatment of respiratory syncytial virus (RSV) infections. Clinical trials; Potency against RSV; Issues on costs.


Related Articles

  • Palivizumab: A Viewpoint by Siva Subramanian. Subramanian, S. // Drugs;Aug1999, Vol. 58 Issue 2, p312 

    Comments on the use of humanized monoclonal antibodies called palivizumab in the treatment of respiratory syncytial virus (RSV) infection. Background on RSV; Description of palivizumab; Considerations in the volume used through intramascular administration.

  • Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations. Paes, B.; Mitchell, I.; Li, A.; Lanctôt, K.L. // European Journal of Pediatrics;May2012, Vol. 171 Issue 5, p833 

    Palivizumab utilization, compliance, and outcomes were examined in infants with preexisting medical diseases within the Canadian Registry Database (CARESS) to aid in developing guidelines for potential 'at-risk' infants in the future. Infants who received ≥1 dose of palivizumab during the...

  • Phage Display-based Strategies for Cloning and Optimization of Monoclonal Antibodies Directed against Human Pathogens. Clementi, Nicola; Mancini, Nicasio; Solforosi, Laura; Castelli, Matteo; Clementi, Massimo; Burioni, Roberto // International Journal of Molecular Sciences;Jul2012, Vol. 13 Issue 7, p8273 

    In the last two decades, several phage display-selected monoclonal antibodies (mAbs) have been described in the literature and a few of them have managed to reach the clinics. Among these, the anti-respiratory syncytial virus (RSV) Palivizumab, a phage-display optimized mAb, is the only marketed...

  • Pharmacologic Advances in the Treatment and Prevention of Respiratory Syncytial Virus. Empey, Kerry M.; Peebles Jr, R. Stokes; Kolls, Jay K. // Clinical Infectious Diseases;5/1/2010, Vol. 50 Issue 9, p1258 

    Currently, only 2 drugs have been approved for the treatment of respiratory syncytial virus (RSV). Palivizumab is a monoclonal antibody for the prevention of RSV in high-risk children. Ribavirin is approved for treatment of severe RSV disease; however, its effectiveness in improving outcomes is...

  • Palivizumab is highly effective in suppressing respiratory syncytial virus in an immunosuppressed animal model. Ottolini, M. G.; Curtis, S. R.; Mathews, A.; Ottolini, S. R.; Prince, G. A. // Bone Marrow Transplantation;1/15/2002, Vol. 29 Issue 2, p117 

    Focuses on a study which tested the efficacy of the systemic monoclonal antibody, palivizumab for prophylaxis and therapy of respiratory syncytial virus. Materials and methods; Results; Discussion.

  • Human Monoclonal Antibodies Isolated from Spontaneous Epstein-Barr Virus-Transformed Tumors of Hu-SPL-SCID Mice and Specific for Fusion Protein Display Broad Neutralizing Activity Toward Respiratory Syncytial Virus. Chamat, Soulaima; Walsh, Edward E.; Anderson, Darrell; Osta, Mike; Awaraji, Christian; Li-Zhen Pan; Ochi, James; Shuey, Steve; Brams, Peter // Journal of Infectious Diseases;8/1/99, Vol. 180 Issue 2 

    Investigates the use of human monoclonal antibody in determining the fusion protein of human respiratory syncytial virus (RSV). Types of RSV genus; Effectiveness of immunotherapy with virus-neutralizing antibodies in treating RSV infection; Generation of high-affinity human monoclonal antibodies.

  • Literature Reviews: Neonatology.  // Clinical Pediatrics;Sep1999, Vol. 38 Issue 9, p556 

    Presents a summary of the study `Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants' from the 1998 issue of the `Pediatrics' journal.

  • Trends in the Development and Approval of Monoclonal Antibodies for Viral Infections. Reichert, Janice M. // BioDrugs;2007, Vol. 21 Issue 1, p1 

    Monoclonal antibodies (mAbs) developed for either the prevention or treatment of viral diseases represent a small, but valuable, class of products. Since 1985, commercial firms have initiated clinical studies involving a total of 28 mAbs. To date, one product (palivizumab) has been approved...

  • This new drug may help prevent RSV disease. Cerrato, Paul L. // RN;Jun96, Vol. 59 Issue 6, p69 

    Reports on the development of the plasma-derived antibody called RespiGam for the prevention of respiratory syncytial virus (RSV) disease.


Read the Article

Courtesy of

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics